1
|
Hawman DW, Haddock E, Meade-White K, Nardone G, Feldmann F, Hanley PW, Lovaglio J, Scott D, Komeno T, Nakajima N, Furuta Y, Gowen BB, Feldmann H. Efficacy of favipiravir (T-705) against Crimean-Congo hemorrhagic fever virus infection in cynomolgus macaques. Antiviral Res 2020; 181:104858. [PMID: 32645335 PMCID: PMC11056077 DOI: 10.1016/j.antiviral.2020.104858] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2020] [Revised: 06/08/2020] [Accepted: 06/12/2020] [Indexed: 01/29/2023]
Abstract
Crimean-Congo hemorrhagic fever virus (CCHFV) is a widely distributed hemorrhagic fever virus found throughout Eastern Europe, Africa, the Middle East and Asia. It is spread through bites from infected ticks, animal husbandry and can also be acquired in the healthcare setting during care of infected patients. In humans, CCHFV can cause a sudden onset of a non-specific febrile illness that can rapidly progress to severe hemorrhagic manifestations. Currently, there is no widely available vaccine and although ribavirin has been suggested for the treatment of CCHFV, clinical efficacy in both animal models and humans is inconsistent suggesting more potent antivirals are needed for CCHFV. Favipiravir is approved in Japan for the treatment of influenza virus infections and has shown promise against other highly pathogenic RNA viruses including CCHFV with demonstrated efficacy in the type I interferon deficient mouse model. In this report we utilized the cynomolgus macaque model to evaluate the efficacy of once- and twice-daily favipiravir treatment against CCHFV infection. We found that favipiravir treatment suppressed viremia and viral shedding when treatment was initiated 24 h post-infection and viral burdens in key tissues trended lower in favipiravir-treated animals. Our data indicate that favipiravir has efficacy against CCHFV in vivo in a non-human primate model of infection.
Collapse
Affiliation(s)
- David W Hawman
- Rocky Mountain Laboratories, NIAID/NIH, Hamilton, MT, USA.
| | - Elaine Haddock
- Rocky Mountain Laboratories, NIAID/NIH, Hamilton, MT, USA
| | | | - Glenn Nardone
- Research Technologies Branch, NIAID/NIH, Rockville, MD, USA
| | | | | | - Jamie Lovaglio
- Rocky Mountain Laboratories, NIAID/NIH, Hamilton, MT, USA
| | - Dana Scott
- Rocky Mountain Laboratories, NIAID/NIH, Hamilton, MT, USA
| | | | | | | | | | - Heinz Feldmann
- Rocky Mountain Laboratories, NIAID/NIH, Hamilton, MT, USA.
| |
Collapse
|
2
|
Abstract
Crimean-Congo hemorrhagic fever virus (CCHFV) is a widely distributed hemorrhagic fever virus and the cause of hemorrhagic disease in Africa, Southern and Eastern Europe, the Middle East, India and Asia. Recent emergence of CCHFV into Spain indicates that the geographic range of this virus is expanding and the presence of its tick vector in several countries without reported disease suggest that CCHFV will continue to spread. Research into CCHFV was historically limited by a lack of suitable animal models and tools to study viral pathogenesis. However, in the past few years the toolset for studying CCHFV has expanded with small animal and non-human primate models for CCHFV being developed along with a reverse genetics system that allows for investigation of viral determinants of disease. These tools have been utilized to understand how CCHFV antagonizes host restriction factors and to develop novel vaccine candidates that may help limit the substantial morbidity and mortality in humans caused by CCHFV.
Collapse
Affiliation(s)
- David W Hawman
- Laboratory of Virology, Division of Intramural Research, NIAID/NIH, Hamilton, Montana, 59840, USA
| | - Heinz Feldmann
- Laboratory of Virology, Division of Intramural Research, NIAID/NIH, Hamilton, Montana, 59840, USA
| |
Collapse
|
3
|
Abstract
Crimean-Congo haemorrhagic fever (CCHF) is a tick-borne infectious disease characterized by fever, malaise, headache, nausea, vomiting, diarrhoea, sore throat, muscle aches, haemorrhage and thrombocytopenia. It is a challenge for the population of endemic rural areas, and for healthcare workers, and carries a considerable mortality. The disease is widely distributed in Africa, Europe and Asia, and has become a serious threat to public health in Eurasia. The intention of this review is to summarize the current status of CCHF in Eurasia.
Collapse
Affiliation(s)
- Hakan Leblebicioglu
- Department of Infectious Diseases and Clinical Microbiology, Ondokuz Mayis University Medical School, Samsun, Turkey.
| |
Collapse
|